Literature DB >> 4030767

Purification and characterization of human lipoprotein lipase and hepatic triglyceride lipase. Reactivity with monoclonal antibodies to hepatic triglyceride lipase.

C F Cheng, A Bensadoun, T Bersot, J S Hsu, K H Melford.   

Abstract

Human lipoprotein lipase and hepatic triglyceride lipase were purified to homogeneity from post-heparin plasma. These enzymes were purified 250,000- and 100,000-fold with yields of 27 +/- 15 and 19 +/- 6%, respectively. Molecular weight determination by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate and reducing agents yielded Mr of 60,500 +/- 1,800 and 65,200 +/- 400, respectively, for lipoprotein lipase and hepatic triglyceride lipase. These lipase preparations were shown to be free of detectable antithrombin by measuring its activity and by probing of Western blots of lipases with a monospecific antibody against antithrombin. In additions, probing of Western blots with concanavalin A revealed no glycoproteins corresponding to the molecular weight of antithrombin. Four stable hybridoma-producing distinct monoclonal antibodies (mAb) to hepatic triglyceride lipase were isolated. The specificity of one mAb, HL3-5, was established by its ability to immunoprecipitate hepatic triglyceride lipase catalytic activity. Interaction of HL3-5 with this lipase did not inhibit catalytic activity. The three other mAb interacted with hepatic triglyceride lipase only after denaturation of the enzyme with detergents. The relatedness of these two enzymes was examined by comparing under the same conditions the thermal inactivation, the sensitivity to sulfhydryl and reducing agents, amino acid composition, and the mobility of peptide fragments generated by cyanogen bromide cleavage. The results of these studies strongly support the view that the two enzymes are different proteins. Immunological studies confirm this conclusion. Four mAb to hepatic triglyceride lipase did not interact with lipoprotein lipase in Western blots, enzyme-linked immunosorbent assay, and immunoprecipitation experiments. These immunological studies demonstrate that several epitopes of the hepatic triglyceride lipase protein moiety are not present in the lipoprotein lipase molecule.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4030767

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  A new monoclonal antibody, 4-1a, that binds to the amino terminus of human lipoprotein lipase.

Authors:  André Bensadoun; Charlene D Mottler; Chris Pelletier; Daniel Wu; Jane J Seo; Calvin S Leung; Oludotun Adeyo; Chris N Goulbourne; Peter Gin; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  Biochim Biophys Acta       Date:  2014-03-28

2.  Unfolding of monomeric lipoprotein lipase by ANGPTL4: Insight into the regulation of plasma triglyceride metabolism.

Authors:  Kristian K Kristensen; Katrine Zinck Leth-Espensen; Haydyn D T Mertens; Gabriel Birrane; Muthuraman Meiyappan; Gunilla Olivecrona; Thomas J D Jørgensen; Stephen G Young; Michael Ploug
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-07       Impact factor: 11.205

3.  Distinct immunoreactivities suggest the existence of potential tissue variants in rat lipoprotein lipase.

Authors:  A Soteriou; A Cryer
Journal:  Biochem J       Date:  1994-04-15       Impact factor: 3.857

4.  Molecular studies on primary lipoprotein lipase (LPL) deficiency. One base deletion (G916) in exon 5 of LPL gene causes no detectable LPL protein due to the absence of LPL mRNA transcript.

Authors:  A Takagi; Y Ikeda; Z Tsutsumi; T Shoji; A Yamamoto
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

5.  Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins.

Authors:  J Fan; J Wang; A Bensadoun; S J Lauer; Q Dang; R W Mahley; J M Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

6.  The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain.

Authors:  Simon Mysling; Kristian Kølby Kristensen; Mikael Larsson; Anne P Beigneux; Henrik Gårdsvoll; Loren G Fong; André Bensadouen; Thomas Jd Jørgensen; Stephen G Young; Michael Ploug
Journal:  Elife       Date:  2016-01-03       Impact factor: 8.140

7.  The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding.

Authors:  Simon Mysling; Kristian Kølby Kristensen; Mikael Larsson; Oleg Kovrov; André Bensadouen; Thomas Jd Jørgensen; Gunilla Olivecrona; Stephen G Young; Michael Ploug
Journal:  Elife       Date:  2016-12-08       Impact factor: 8.140

8.  Using Synthetic ApoC-II Peptides and nAngptl4 Fragments to Measure Lipoprotein Lipase Activity in Radiometric and Fluorescent Assays.

Authors:  Dean Oldham; Hong Wang; Juliet Mullen; Emma Lietzke; Kayla Sprenger; Philip Reigan; Robert H Eckel; Kimberley D Bruce
Journal:  Front Cardiovasc Med       Date:  2022-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.